Final Program

236 TUESDAY • MAY 17
CLINICAL
YEAR IN REVIEW
CME Credits Available: 2.0
C1 CLINICAL YEAR IN REVIEW 3
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Gateway Ballroom 102-104 (South Building, Lower Level)
Target Audience
Providers including physicians, nurses, respiratory therapists, nurse practitioners,
physician assistants. Trainees including residents and fellows; clinical researchers.
Objectives
At the conclusion of this session, the participant will be able to:
• apply new clinical research knowledge to clinical practice;
• learn new findings about key conditions in pulmonary, critical care and sleep;
• have new strategies to manage the care of common conditions in pulmonary,
critical care, and sleep.
The annual Clinical Year in Review symposia topic reviews of the key clinical
research publications over the last year. Each speaker is asked to review the 5-7
most important and influential publications on their topic in the prior year.
Chairing: J.L. Taylor-Cousar, MD, Denver, CO
D.J. Lederer, MD, MS, New York, NY
D.W. Ford, MD, MSCR, Charleston, SC
9:00 Palliative Care
C.E. Cox, MD, MPH, Durham, NC
9:30 Lung Cancer
N.T. Tanner, MD, MSCR, Charleston, SC
10:00 Sleep in Critical Illness
R.L. Owens, MD, La Jolla, CA
10:30 Sleep Disordered Breathing
J.L. Pepin, MD, PhD, Grenoble, France
This session and the International Conference are supported by an educational grant from
AstraZeneca LP.
All CME sessions have been planned and implemented in accordance with the Essential
Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME)
and are free of the control of commercial interests.
C2
CLINICAL
CLINICAL TOPICS IN PULMONARY MEDICINE
CME Credits Available: 2.0
TOBACCO SMOKING AND CESSATION IN
VULNERABLE POPULATIONS
Assemblies on Clinical Problems; Behavioral Science and Health
Services Research
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 135 (North Building, Lower Level)
Target Audience
Physicians, nurses, public health officials, physicians in training.
Objectives
At the conclusion of this session, the participant will be able to:
• enhance the knowledge of smoking behaviors and smoking cessation
therapies in different subpopulations;
• become aware of targeted or customized treatment options for smoking
cessation;
• understand and become aware of the risks of light or moderate smoking.
Tobacco smoking is a major risk factor for a variety of diseases. Tobacco
smoking substantially impacts respiratory, cardiac, and vascular health resulting
in excess health care costs and premature loss of life. Some ethnic groups and
communities are disproportionately impacted, manifesting greater risk of
smoking-related lung cancer and death. This session explores the state of the
knowledge on the genetics of tobacco smoking and smoking cessation; tobacco
use in several ethnic groups; and targeted smoking cessation programs.
Chairing: M.G. Foreman, MD, Atlanta, GA
D.J. Upson, MA, MD, Albuquerque, NM
9:00 Tobacco Use in African Americans
E.R. Neptune, MD, Baltimore, MD
9:25 Tobacco Use in Latinos
F. Holguin, MD, MPH, Pittsburgh, PA
9:50 Ethnic Variation in Lung Cancer Among Smokers
M.P. Rivera, MD, Chapel Hill, NC
10:15 Best Approaches to Smoking Cessation in Targeted Groups
M. Castro, MD, MPH, St. Louis, MO
10:40 Genetics of Tobacco Addiction and Smoking Cessation
M.G. Foreman, MD, Atlanta, GA
C3
CLINICAL • TRANSLATIONAL
CLINICAL TOPICS IN PULMONARY MEDICINE
CME Credits Available: 2.0
KEY MANAGEMENT CONSIDERATIONS IN
SARCOIDOSIS
Assemblies on Clinical Problems; Allergy, Immunology and Inflammation
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 134 (North Building, Lower Level)
Target Audience
Practitioners who actively care for patients with sarcoidosis, as well as
investigators involved in clinical or translational sarcoidosis studies.
Objectives
At the conclusion of this session, the participant will be able to:
• screen for and diagnose cardiac sarcoidosis;
• understand when to start immunosuppression for pulmonary sarcoidosis
and for other “dangerous” sarcoidosis phenotypes;
• devise a steroid sparing treatment regimen, and know better how to counsel
patients on the rationale for the various options.
We begin this session by a review of the pathophysiology of sarcoidosis from
the perspective of providing rationale for treatment strategies. We then highlight
ATS 2016 • San Francisco